Developmental DMPK: in vitro Drug-Drug Interaction Studies

WuXi AppTec DMPK offers the full panel of enzyme and transporter assays required by the FDA and EMA guidelines for the in vitro assessment of drug-drug interactions. These tests allow Sponsors to plan (and sometimes waive) clinical drug-drug interaction studies.


  • CYP inhibition (7-9 CYPs) – direct (DI) and time-dependent (TDI).
  • CYP Induction (mRNA and activity based -1A2, 2B6, 3A4)
  • CYP and UGT/FMO Phenotyping

Transporters – Substrate and Inhibitor assays

  • Membrane vesicles – efflux transporters (BCRP, P-gp, BSEP, MRP2, MRP3, MRP4)
  • Cell-based assays:
  • Uptake – OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, PEPT1, 2, MATE1, 2K, NTCP, ASBT
  • Efflux – transfected MDCKII and Caco-2 cells(BCRP and P-gp)
  • Double transfected MDCKII cells (BCRP±OATP2B1)